PMV Pharmaceuticals, Inc.

Equities

PMVP

US69353Y1038

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:31:52 23/05/2024 BST			5-day change	1st Jan Change
2.065 ^USD	-2.59%		-3.26%	-32.90%

05-09	PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-12	Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target	MT

PMV Pharmaceuticals, Inc. Appoints Guillermina Lozano to Scientific Advisory Board

February 16, 2021 at 01:00 pm

PMV Pharmaceuticals, Inc. announced the appointment of Guillermina (Gigi) Lozano, Ph.D., to its Scientific Advisory Board (SAB). Dr. Guillermina (Gigi) Lozano is a geneticist recognized for her studies of the p53 tumor suppressor pathway, from characterizing p53 as a transcriptional activator to characterizing the physiological importance of Mdm2 and Mdm4 proteins as inhibitors of p53, and the consequences of p53 mutations on tumor development.

Latest news about PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target	04-12	MT
PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	03-27	CI
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer	03-18	CI
North American Morning Briefing : Stock Futures -2-	03-06	DJ
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%	01-18	CI
PMV Pharmaceuticals Names Michael Carulli as CFO; Phase 2 Trial of Tumor Treatment on Track	01-05	MT
PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes	01-05	CI
PMV Pharmaceuticals, Inc. Announces Executive Changes	01-05	CI
Ladenburg Thalmann Initiates PMV Pharmaceuticals at Buy With $7 Price Target	12-27	MT
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from NASDAQ Biotechnology Index	12-15	CI
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
HC Wainwright Cuts Price Target on PMV Pharmaceuticals to $5 From $29, Maintains Buy Rating	16/10/23	MT
PMV Pharmaceuticals Says Updated Trial Data Show Cancer Therapy Induces Anti-Tumor Activity; Shares Fall	12/10/23	MT
PMV Pharmaceuticals, Inc. Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types with TP53 Y220C Mutation	12/10/23	CI
PMV Pharmaceuticals, Inc. to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	20/09/23	CI
HC Wainwright Adjusts PMV Pharmaceuticals Price Target to $29 From $35, Maintains Buy Rating	11/08/23	MT
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
HC Wainwright Adjusts Price Target on PMV Pharmaceuticals to $35 From $36, Keeps Buy Rating	20/03/23	MT
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from S&P Biotechnology Select Industry Index	20/03/23	CI
Oppenheimer Adjusts PMV Pharmaceuticals' Price Target to $15 From $28, Maintains Outperform Rating	02/03/23	MT
PMV Pharmaceuticals Proposes $200 Million Mixed Shelf Offering	02/03/23	MT
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/03/23	CI

Chart PMV Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.12 USD

Average target price

5.75 USD

Spread / Average Target

+171.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PMV PHARMACEUTICALS, INC.	-32.90%	109M
MODERNA, INC.	+64.91%	62.59B
IQVIA HOLDINGS INC.	-2.01%	41.18B
LONZA GROUP AG	+44.70%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+12.70%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.74%	19.09B
BIO-TECHNE CORPORATION	+5.66%	13.08B
UNITED THERAPEUTICS CORPORATION	+24.96%	12.26B
MEDPACE HOLDINGS, INC.	+28.50%	12.05B

Other Biotechnology & Medical Research